Full View

Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination

I Kister, R Curtin, AL Piquet, T Borko, J Pei… - Annals of Clinical and … - Wiley Online Library
Objectives (1) To plot the trajectory of humoral and cellular immune responses to the primary
(two‐dose) COVID‐19 mRNA series and the third/booster dose in B‐cell‐depleted multiple …
相关文章

Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination

I Kister, R Curtin, AL Piquet, T Borko, J Pei, BL Banbury… - medRxiv, 2024 - medrxiv.org
Objectives: 1. To plot the trajectory of humoral and cellular immune responses to the primary
(two-dose) COVID-19 mRNA series and the third/booster dose in B-cell-depleted multiple …

Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination.

I Kister, R Curtin, AL Piquet, T Borko, J Pei… - Annals of Clinical and …, 2024 - europepmc.org
Objectives (1) To plot the trajectory of humoral and cellular immune responses to the primary
(two-dose) COVID-19 mRNA series and the third/booster dose in B-cell-depleted multiple …

Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination

I Kister, R Curtin, AL Piquet, T Borko… - Annals of clinical … - pubmed.ncbi.nlm.nih.gov
Objectives (1) To plot the trajectory of humoral and cellular immune responses to the primary
(two-dose) COVID-19 mRNA series and the third/booster dose in B-cell-depleted multiple …

Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination

I Kister, R Curtin, AL Piquet, T Borko, J Pei, BL Banbury… - 2024 - europepmc.org
Objectives: 1. To plot the trajectory of humoral and cellular immune responses to the primary
(two-dose) COVID-19 mRNA series and the third/booster dose in B-cell-depleted multiple …